Vanda Pharmaceuticals Inc. (VNDA) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. Founded in 2002 and headquartered in Washington D.C., the company is dedicated to the advancement of a diverse portfolio of products and product candidates, including both proprietary compounds and co-developed strategic partnerships.
One of Vanda's primary goals is to develop and commercialize products that can treat disorders of the central nervous system, where the potential health impact is significant and the demand for better treatment options is high. The range of disorders includes schizophrenia, jet lag disorder, and various sleep disorders among others.
Vanda Pharmaceuticals has two products in the market: Fanapt (iloperidone) and Hetlioz (tasimelteon). Fanapt is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia in adults, while Hetlioz is used to treat sleep and wake disorders. Both of these FDA-approved products highlight Vanda's commitment to robust scientific discovery and the pursuit of novel treatments.
Vanda's business strategy is based around the identification, development, and commercialization of late-stage product candidates. One of the remarkable characteristics of Vanda's pipeline is the advanced state of their clinical programs. The company invests highly in research and development to ensure its position at the forefront of innovative healthcare solutions.
Despite its primary focus on central nervous system disorders, Vanda is also dedicated to developing treatments for other health problems. This include bacterial infections, ocular diseases, and oncology. The company is involved in multiple partnerships with leading pharmaceutical companies to co-develop these treatments, facilitating the broad distribution of their products globally.
From a financial perspective, Vanda Pharmaceuticals is a publicly-traded company listed on the NASDAQ stock exchange under ticker symbol 'VNDA'. It has garnered the attention and backing of several prominent investors and institutions due to its pioneering work in the biopharmaceutical space.
Vanda Pharmaceuticals is committed to the patients it serves and aims to enrich their lives by providing effective therapeutic solutions. The company's vision is to become a global leader in the biopharmaceutical industry by continuously pushing the boundaries of medical innovation. It stands as an ongoing testament to the role innovation and dedication can play in improving healthcare outcomes worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Vanda Pharmaceuticals announced that its NEREUS™ sponsored No. 47 IndyCar, driven by Mick Schumacher for Rahal Letterman Lanigan Racing, will compete in the inaugural Freedom 250 Grand Prix in Washington, D.C. This historic NTT INDYCAR SERIES race on the National Mall celebrates America's 250th anniversary. NEREUS™ (tradipitant) is the first new U.S. prescription medication approved for the prevention of motion-induced vomiting in 47 years.
Vanda Pharmaceuticals has received European Commission orphan designation for its drug imsidolimab for the treatment of generalized pustular psoriasis (GPP). This designation, the first for a GPP treatment in the EU, offers benefits like regulatory assistance and market exclusivity. Imsidolimab is also under FDA review in the U.S. with a target action date of December 12, 2026.
Vanda Pharmaceuticals Inc. announced that its NEREUS™ sponsored No. 47 IndyCar, driven by Mick Schumacher, will compete in the inaugural Freedom 250 Grand Prix in Washington, D.C. The race, held on the National Mall, celebrates America's 250th anniversary. NEREUS™ (tradipitant) is an FDA-approved medication for motion-induced vomiting, and this sponsorship highlights the brand's focus on performance.
Vanda Pharmaceuticals' fair value has been reduced from $14.90 to $12.19, reflecting a modest downgrade in its intrinsic value estimate. Analysts trimmed their price target from $17 to $12 due to a Q2 revenue miss, updated revenue growth expectations, and revised profit margins. The company reiterated its full-year 2026 revenue guidance between US$240 million and US$290 million and received Rare Pediatric Disease Designation for its investigational therapy VCA-894A.